Disclosures for "A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Efficacy, Safety and Tolerability of Ulixacaltamide in Adults with Parkinson’s Disease and Motor Fluctuations")